Researcher Profile

Researcher Profile

W. Christopher Ehmann, MD

W. Christopher Ehmann, MD

Professor, Department of Medicine
Division of Hematology and Oncology
Disease Teams:
Bone Marrow Transplantation
Leukemia and Lymphoma
wce4@psu.edu

Research Interests

  • Therapeutics
  • Acute Myeloid Leukemia
  • T-Lymphocytes
  • Leukemia
  • HIV
  • B-Cell Lymphoma
  • Survival
  • Drug Therapy
  • Skin
  • Cell Transplantation
  • Non-Hodgkin's Lymphoma
  • Afibrinogenemia

Clinical Trials

MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Rearrangements
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor).
Blood and Bone Marrow Collection from Patients with Hematological Malignancies for Study of Anti-Tumor Immunity
Collection of Blood for Investigation and Characterization of Circulating Tumor Cells (CTCs) in Cancer Patients with Microdevices
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
T-Cell Exhaustion in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation
Protocol for a Research Database for Hematopoietic Cell Transplantation, other Cellular Therapies and Marrow Toxic Injuries.

Recent Publications

2019

Jia, B, Zhao, C, Rakszawski, KL, Claxton, D, Ehmann, WC, Rybka, W, Mineishi, S, Wang, M, Shike, H, Bayerl, M, Sivik, JM, Schell, T, Drabick, J, Hohl, R & Zheng, H 2019, 'Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia', Cancer Research, vol. 79, no. 7, pp. 1635-1645. https://doi.org/10.1158/0008-5472.CAN-18-3107
Spurgeon, SE, Sharma, K, Claxton, D, Ehmann, WC, Pu, J, Shimko, S, Stewart, A, Subbiah, N, Palmbach, G, LeBlanc, F, Latour, E, Chen, YY, Mori, M, Hasanali, Z & Epner, EM 2019, 'Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma', British Journal of Haematology. https://doi.org/10.1111/bjh.16008

2018

Jia, B, Wang, L, Claxton, D, Ehmann, WC, Rybka, W, Mineishi, S, Rizvi, S, Shike, H, Bayerl, M, Schell, T, Hohl, R & Zheng, H 2018, 'Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients', Blood Cancer Journal, vol. 8, no. 3, 34. https://doi.org/10.1038/s41408-018-0069-4
Wang, L, Jia, B, Claxton, D, Ehmann, WC, Rybka, W, Mineishi, S, Naik, S, Khawaja, MR, Sivik, J, Han, J, Hohl, R & Zheng, H 2018, 'VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML' OncoImmunology, vol. 7, no. 9, e1469594. https://doi.org/10.1080/2162402X.2018.1469594

2017

Zhu, L, Kong, Y, Zhang, J, Claxton, D, Ehmann, WC, Rybka, W, Palmisiano, ND, Wang, M, Jia, B, Bayerl, M, Schell, T, Hohl, R, Zeng, H & Zheng, H 2017, 'Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia', Journal of Hematology and Oncology, vol. 10, no. 1, 124. https://doi.org/10.1186/s13045-017-0486-z
Teye, EK, Sido, A, Xin, P, Finnberg, NK, Gokare, P, Imamura, Y, Salzberg, AC, Shimko, S, Bayerl, M, Ehmann, WC, Claxton, D, Rybka, W, Drabick, J, Wang, H-G, Abraham, T, El-Deiry, WS, Brodsky, RA, J.Hohl, R & Pu, J 2017, 'PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features' Oncotarget, vol. 8, no. 18, pp. 29887-29905. https://doi.org/10.18632/oncotarget.15136

2016

Goy, A, Forero, A, Wagner-Johnston, N, Ehmann, WC, Tsai, M, Hatake, K, Ananthakrishnan, R, Volkert, A, Vandendries, E & Ogura, M 2016, 'A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy', British Journal of Haematology, vol. 174, no. 4, pp. 571-581. https://doi.org/10.1111/bjh.14094
Santos, MA, Ehmann, WC & Rybka, W 2016, 'Keep Your Eyes Peeled: Chemosis and Proptosis from Relapsed Leukemia' American Journal of Medicine, vol. 129, no. 7, pp. e69-e70. https://doi.org/10.1016/j.amjmed.2016.01.040
Williams, ME, Hong, F, Gascoyne, RD, Wagner, LI, Krauss, JC, Habermann, TM, Swinnen, LJ, Schuster, SJ, Peterson, CG, Sborov, MD, Martin, SE, Weiss, M, Ehmann, WC, Horning, SJ & Kahl, BS 2016, 'Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402', British Journal of Haematology, vol. 173, no. 6, pp. 867-875. https://doi.org/10.1111/bjh.14007
Kong, Y, Zhu, L, Schell, T, Zhang, J, Claxton, D, Ehmann, WC, Rybka, W, George, M, Zeng, H & Zheng, H 2016, 'T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients', Clinical Cancer Research, vol. 22, no. 12, pp. 3057-3066. https://doi.org/10.1158/1078-0432.CCR-15-2626

2015

Kong, Y, Zhang, J, Claxton, D, Ehmann, WC, Rybka, W, Zhu, L, Zeng, H, Schell, T & Zheng, H 2015, ' PD-1 hi TIM-3 + T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation ', Blood Cancer Journal, vol. 5, no. 7, e330. https://doi.org/10.1038/bcj.2015.58
Wagner-Johnston, ND, Goy, A, Rodriguez, MA, Ehmann, WC, Hamlin, PA, Radford, J, Thieblemont, C, Suh, C, Sweetenham, J, Huang, Y, Sullivan, ST, Vandendries, ER & Gisselbrecht, C 2015, 'A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma', Leukemia and Lymphoma, vol. 56, no. 10, pp. 2863-2869. https://doi.org/10.3109/10428194.2015.1017821
Abbi, KKS, Rybka, W, Ehmann, WC & Claxton, D 2015, 'Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia' Clinical Lymphoma, Myeloma and Leukemia, vol. 15, no. 1, pp. 41-46. https://doi.org/10.1016/j.clml.2014.06.005

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)